Endothelial activation by angiotensin II through NFκB and p38 pathways: Involvement of NFκB‐inducible kinase (NIK), free oxygen radicals, and selective inhibition by aspirin

Abstract

Angiotensin-II (AII), the dominant effector of the renin–angiotensin system, is involved in the pathogenesis of cardiovascular diseases, such as atherosclerosis. Upregulation of the adhesion molecules VCAM-1, ICAM-1, and E-selectin in endothelial cells by inflammatory cytokines through nuclear factor kappa B (NFκB) activation is implicated in formation and progression of atherosclerotic plaque. Here we show that AII induces NFκB-dependent transcription in primary endothelial cell lines, leading to the upregulation of ICAM-1 and VCAM-1 expression. NFκB activation by AII is mediated by the NFκB-inducing kinase (NIK), a common mediator of NFκB activation by inflammatory cytokines, such as TNF-α. However, NFκB stimulation by AII differs from that of TNF-α since a TNF-receptor associated factor 2 (TRAF-2) dominant negative mutant does not prevent AII-mediated NFκB activation. In analogy with TNF-α-dependent activation of NFκB, treatment with either the anti-oxidant N-acetyl cysteine (NAC) or the cyclooxygenase (COX) inhibitor acetyl salicylic acid (aspirin), but not indometacin, prevents the induction of NFκB-dependent transcription by AII. Thus, production of reactive oxygen species, aspirin (asp)-sensitive enzymes of the arachidonate metabolism, and NIK are common transducers of AII- and TNF-dependent pathways to NFκB. AII also activates the inflammatory p38 kinase in endothelial cells, an effect inhibited by exposure to either NAC or asp. Pharmacological interference of the p38 pathway, with the inhibitor SB 202190, prevented AII-mediated activation of the NFκB target V-CAM, without affecting degradation of IκBα. These results support a pro-inflammatory effect of the vasoactive peptide AII in endothelial cells, through at least two pathways—NFκB and p38—both of which are sensitive to asp and antioxidants.